Recordati Stock Quote REC - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

59.60

Bid

59.25

Ask

60.40

Volume

413,509

59.25 Day's Range 60.30

47.28 52 Week Range 60.50

Market Cap

12.239B

Previous Close

60.95

Open

59.75

Last Trade

340

59.6

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

283,372

Shares Outstanding

205,358,104

Dividend Yield

2.06%

PE Ratio

0.00

Earnings Per Share (EPS)

Revenue

2.07B

Net Profit

389.21M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.recordati.it

Headquarters

Milan, Lombardy, Ita

Founded

1926

Recordati SpA is listed in the Pharmaceutical Preparations sector of the Italian Stock Exchange with ticker REC. The last closing price for Recordati was 60.95 €. Over the last year, Recordati shares have traded in a share price range of 47.28 € to 60.50 €.

Recordati currently has 205,358,104 shares outstanding. The market capitalization of Recordati is 12.52 € billion.

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED...

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5...

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE Milan, 4th October 2024 –...

Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease

The LINC 4 study demonstrated superiority of Isturisa® (osilodrostat) over placebo in achieving cortisol normalisation during the 12-week...

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICON...

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICONFERMANO...

Recordati Rare Diseases : Les résultats positifs de l’étude LINC 4 de Phase III présentés aujourd’hui au congrès ann...

Les résultats significatifs de l’étude pivot LINC 4 de Phase III démontrent qu’Isturisa® (osilodrostat) permet une normalisation rapide et...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	2	3.47222222222	57.6	60.5	57.55	352950	59.15084768	DE
4	4.8	8.75912408759	54.8	60.5	54.15	314620	57.55199978	DE
12	8.75	17.2074729597	50.85	60.5	49.16	283372	54.09411436	DE
26	9.78	19.6306704135	49.82	60.5	48.58	258573	52.86989754	DE
52	9.3	18.4890656064	50.3	60.5	47.28	248586	51.60893245	DE
156	15.08	33.8724168913	44.52	60.5	34.52	237399	45.92585275	DE
260	18.22	44.0309328178	41.38	60.5	28.26	280671	45.42416048	DE

REC - Frequently Asked Questions (FAQ)

What is the current Recordati share price?

The current share price of Recordati is 59.60 €

How many Recordati shares are in issue?

Recordati has 205,358,104 shares in issue

What is the market cap of Recordati?

The market capitalisation of Recordati is EUR 12.52B

What is the 1 year trading range for Recordati share price?

Recordati has traded in the range of 47.28 € to 60.50 € during the past year

What is the reporting currency for Recordati?

Recordati reports financial results in EUR

What is the latest annual turnover for Recordati?

The latest annual turnover of Recordati is EUR 2.07B

What is the latest annual profit for Recordati?

The latest annual profit of Recordati is EUR 389.21M

What is the registered address of Recordati?

The registered address for Recordati is VIA MATTEO CIVITALI 1, MILAN, LOMBARDY, 20148

What is the Recordati website address?

The website address for Recordati is www.recordati.it

Which industry sector does Recordati operate in?

Recordati operates in the PHARMACEUTICAL PREPARATIONS sector

Symbol	Price	Vol.
1TMVTeamViewer SE	12.55 € (17.34%)	250
1ROKURoku Inc	94.73 € (15.91%)	220
1ABNBAirbnb Inc	154.50 € (15.37%)	618
1MATMattel Inc	21.56 € (13.21%)	20
BBastogi Spa	0.594 € (12.93%)	185.26k
WPAL26Palingeo SpA	0.2003 € (-29.94%)	62.4k
WTFINTrevi Finanziaria Industriale Spa	0.751 € (-29.81%)	30
WELESEles Spa	0.0905 € (-24.58%)	1.18k
WS3D25Solid World Group spa	0.1225 € (-20.97%)	105.81k
IPInterpump Group Spa	39.74 € (-15.66%)	1.75M
TITTelecom Italia SpA	0.2738 € (-8.00%)	1.08B
TITRTelecom Italia	0.309 € (-5.07%)	145.87M
ISPIntesa Sanpaolo Spa	4.39 € (0.26%)	53.94M
SPMSaipem Spa	2.291 € (-0.74%)	36.39M
ENELEnel Spa	6.871 € (-0.56%)	21.72M

Symbol

Price

Vol.

TITTelecom Italia SpA

0.2738 €

(-8.00%)

1.08B

TITRTelecom Italia

0.309 €

(-5.07%)

145.87M

ISPIntesa Sanpaolo Spa

4.39 €

(0.26%)

53.94M

SPMSaipem Spa

2.291 €

(-0.74%)

36.39M

ENELEnel Spa

6.871 €

(-0.56%)

21.72M

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Recordati SpA (REC)

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

About Recordati SpA

Ask ADVFN Intelligence (AI)

REC Latest News

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICON...

Recordati Rare Diseases : Les résultats positifs de l’étude LINC 4 de Phase III présentés aujourd’hui au congrès ann...

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

REC - Frequently Asked Questions (FAQ)

Movers

Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Recordati SpA (REC) Quote

Recordati SpA (REC)

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

About Recordati SpA

Ask ADVFN Intelligence (AI)

REC Latest News

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICON...

Recordati Rare Diseases : Les résultats positifs de l’étude LINC 4 de Phase III présentés aujourd’hui au congrès ann...

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

REC - Frequently Asked Questions (FAQ)

Movers

Discussion

Your Recent History

Company

Business

Popular

Get The App

Go Ad-Free